This is a routine early-stage development update with no material financial impact. Monitor for future clinical trial results or partnership announcements that could provide clearer catalysts. Given the micro-cap status and historical volatility, any positive data could drive outsized moves, but this filing alone does not warrant a position change.
Price Chart
Executive Summary
Clearmind Medicine announced successful formulation feasibility study for intranasal delivery of its lead candidate MEAI for alcohol use disorder (AUD). The study demonstrated MEAI can be incorporated into a stable, fully soluble solution for intranasal administration. This is an early-stage, non-financial milestone with no revenue or earnings implications.
Key Facts
- Successful formulation feasibility study for intranasal delivery of MEAI (5-Methoxy-2-aminoindane)
- MEAI is Clearmind's lead proprietary therapeutic candidate for alcohol use disorder (AUD)
- Company holds 19 patent families including 32 granted patents
- Market cap approximately $2M with limited liquidity
Financial Impact
No financial figures reported; early-stage R&D milestone with no immediate revenue or cost impact
Risk Factors
- Early-stage development; no guarantee of clinical success or regulatory approval
- Limited cash runway and potential dilution risk given micro-cap status
- Historical poor performance of prior reports on CMND suggests limited market reaction to non-financial news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-075933 |
| Document: ea0297242-6k_clearmind.htm | 0001213900-26-075933 |
| Document: 0001213900-26-075933-index-headers.html | 0001213900-26-075933 |
| Document: 0001213900-26-075933-index.html | 0001213900-26-075933 |
| Document: 0001213900-26-075933.txt | 0001213900-26-075933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers